Genprex Receives Fast Track Designation From The FDA For Its Small Cell Lung Cancer Drug Candidate
Portfolio Pulse from Benzinga Newsdesk
Genprex has received Fast Track designation from the FDA for its small cell lung cancer drug candidate. This could potentially expedite the drug's development and review process.
July 11, 2023 | 1:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Genprex's stock may see positive movement due to the FDA's Fast Track designation for its small cell lung cancer drug candidate.
Fast Track designation by the FDA is a significant regulatory milestone that can expedite the development and review process of a drug. This news is highly relevant to Genprex and could be seen as a positive development by investors, potentially leading to an increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100